CRISPR-Cas systems, revolutionizing genetic engineering, are derived from a prokaryotic adaptive immune mechanism.  Initially identified in bacteria as clustered regularly interspaced short palindromic repeats alongside CRISPR-associated (Cas) genes, their potential for precise genome editing was not realized until the early 2010s.  Prior to CRISPR, gene editing techniques existed, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), but these methods proved laborious and expensive, requiring bespoke design for each target sequence.  The breakthrough came with the adaptation of the type II CRISPR-Cas9 system, specifically from *Streptococcus pyogenes*, which utilizes a guide RNA molecule to direct the Cas9 nuclease to a specific DNA sequence.  This simplified and significantly reduced the cost and time required for genome editing, triggering an explosion of research across diverse fields.  The simplicity of CRISPR-Cas9's programmable nature allows for targeted gene knockouts, insertions, and even base pair substitutions, offering unprecedented precision and efficiency in manipulating genomes for applications ranging from disease modelling to gene therapy.  However, ongoing research continues to address challenges such as off-target effects and delivery methods.